Researchers led by Dr. Su-Chun Zhang at the University of Wisconsin-Madison Waisman Center are utilizing stem cells in a pre-clinical trial to determine the role of human astrocytes in neurodegenerative diseases such as ALS, Huntington’s disease, and Rhett Syndrome. The team found that, upon integration into the central nervous system, stem cell-derived astrocytes from patients with ALS replace the astrocytes of the host while disrupting motor function, as though the host also had ALS.
The Multiple Sclerosis Society of Canada has funded Canada’s first stem cell clinical trial to treat multiple sclerosis, conducted by researchers at the University of Ottawa. The trial, called MESCAMS [Mesenchymal Stem Cell Therapy for Canadian MS patients], will comprise MSC infusions to the central nervous system to utilize their ability to regulate autoimmune attacks and reduce inflammation in 40 MS patients.
Topics: ALS, Phase III, neural stem cells, multiple sclerosis, stemsaveblog, Brain, clinical trials, Debilitating Diseases, Stemcells, autologousstemcells, Amyotrophic lateral sclerosis, Neurodegenerative disease
As reported on the front page of the New York Times Science section, clinical applications of stem cell based therapies are accelerating at a rate that will revolutionize the medical field in a matter of years. In the United States alone, there are currently over 4000 therapies in clinical trials for the treatment of heart disease, blindness, spinal cord injuries, diabetes, H.I.V., and other diseases, injuries, and traumas.
Topics: Muscular Dystrophy, ALS, Parkinson's, Phase III, multiple sclerosis, Heart, stemsaveblog, Joints, Alzheimer's, burn injuries, Diabetes, Acute Myocardial Infarction, Brain, Heart Failure, clinical trials, Bone, Debilitating Diseases, Phase II, Arthritis, Stemcells, Teeth, autologousstemcells, cartilage, Amyotrophic lateral sclerosis, Brain Tumors, Blindness
A team of researchers at the University of Illinois led by doctors Fei Wang, Qiuhao Qu, and JianJun Cheng, have developed a fast and efficient technique for differentiating stem cells into motor neurons. The researchers added critical signaling molecules and growth factors to the cells much earlier than previous methods, resulting in twice the amount of neurons derived from the cells in half the time.
A team of researchers from the University of Michigan and the University of Emory reported positive results from a phase 1 clinical study utilizing stem cells to treat amyotrophic lateral sclerosis [ALS], Lou Gehrig’s disease. In addition to verifying the safety of the new procedure, the trial revealed some progress in preventing further disease damage to the motor nerves by improving their cellular environment.
Scientists in the US (UC, UCSD) and China (Wuhan) have found a way to convert stem cells into functional neurons. The researchers were able to suppress an RNA-binding protein, inducing the stem cells to become neurons. This gives hope for a treatment for neurodegenerative diseases such as Huntington’s, Parkinson’s, Alzheimer’s, Multiple Sclerosis, and Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's disease), which will afflict one in four Americans over their lifetime.